Revenue
Cost
Profit
| Item | Category | Value | YoY |
|---|---|---|---|
| Sales to customers (note 9) | revenue | 24.06B | 9.91% |
| Investment income, interest | revenue | 229.00M | -31.02% |
| Gross profit | profit | 15.96B | 9.77% |
| Cost of products sold | cost | 8.11B | 10.18% |
| Aggregate | revenue | 16.18B | -27.06% |
| Earnings before provision for taxes on income | profit | 5.99B | -56.06% |
| Selling, marketing and administrative expenses | cost | 6.03B | 18.04% |
| Research and development expense | cost | 3.53B | 9.36% |
| Other (income) expense, net | revenue | 294.00M | -95.98% |
| Interest expense, net of portion capitalized | cost | 272.00M | 33.33% |
| In-process research and development impairments | cost | 36.00M | |
| Restructuring (note 12) | cost | 32.00M | 88.24% |
| Net earnings | profit | 5.24B | -52.40% |
| Provision for taxes on income (note 5) | cost | 755.00M | -71.31% |
| Segment | Value | YoY |
|---|---|---|
| Innovative Medicine | 15.43B | 11.19% |
| MedTech | 8.64B | 7.68% |
| Segment | Value | YoY |
|---|---|---|
| UNITED STATES | 13.33B | 8.33% |
| Europe | 5.85B | 14.44% |
| Asia-Pacific, Africa | 3.59B | 8.46% |
| Western Hemisphere, excluding U.S. | 1.29B | 10.80% |
| Item | Category | Value | YoY |
|---|---|---|---|
| Property, plant and equipment at cost | assets | 54.70B | |
| Cash and cash equivalents | assets | 21.69B | |
| Accounts receivable, after allowance for credit loss, current | assets | 17.72B | |
| Total inventories | assets | 14.58B | |
| Prepaid expense and other assets, current | assets | 4.82B | |
| Marketable securities | assets | 363.00M | |
| Total current assets | assets | 59.17B | |
| Accumulated depreciation, depletion and amortization, property, plant, and equipment | assets | 31.43B | |
| Property, plant and equipment, net | assets | 23.27B | |
| Total intangible assets — net | assets | 49.06B | |
| Goodwill (note 3) | assets | 48.56B | |
| Non current other assets | assets | 14.11B | |
| Deferred income tax assets, net | assets | 6.73B | |
| Assets | assets | 200.89B | |
| Total liabilities | liabilities | 119.71B | |
| Total shareholders’ equity | liabilities | 81.19B | |
| Total current liabilities | liabilities | 57.72B | |
| Non-current debt | liabilities | 37.53B | |
| Other liabilities, noncurrent | liabilities | 10.21B | |
| Deferred income tax liabilities, net | liabilities | 7.01B | |
| Employee-related liabilities | liabilities | 6.76B | |
| Long-term taxes payable (note 5) | liabilities | 486.00M | |
| Total shareholders’ equity | equity | 81.19B | |
| Treasury stock, common, value | equity | 76.26B | |
| Accumulated other comprehensive income (loss), net of tax | equity | 14.83B | |
| Accrued rebates returns and promotions | liabilities | 18.40B | |
| Current debt | liabilities | 17.46B | |
| Accounts payable, current | liabilities | 10.46B | |
| Accrued liabilities, current | liabilities | 7.40B | |
| Employee-related liabilities, current | liabilities | 2.91B | |
| Accrued income taxes, current | liabilities | 1.09B | |
| Aggregate | equity | 172.28B | |
| Retained earnings (accumulated deficit) | equity | 169.16B | |
| Common stock, value, issued | equity | 3.12B |
| Item | Value |
|---|---|
| Net earnings | 5.24B |
| Depreciation and amortization | 2.00B |
| Increase (decrease) in other operating assets | 349.00M |
| Share-based payment arrangement, noncash expense | 300.00M |
| Deferred income tax expense (benefit) | 159.00M |
| Asset write-downs | 36.00M |
| Gain (loss) on sale of assets and asset impairment charges | 12.00M |
| Charges for acquired in-process research and development assets | 2.00M |
| Accounts receivable, credit loss expense (reversal) | -8.00M |
| Increase (decrease) in inventories | -431.00M |
| Increase (decrease) in accounts receivable | -595.00M |
| Decrease in other current and non-current liabilities | -629.00M |
| Increase (decrease) in accounts payable and accrued liabilities | -3.92B |
| Item | Value |
|---|---|
| Proceeds from sale, maturity and collection of investments | 209.00M |
| Proceeds from sale of productive assets | 29.00M |
| Credit support agreements activity, net | -31.00M |
| Payment for (proceeds from) other investing activity | -54.00M |
| Payments to acquire investments | -144.00M |
| Payments to acquire property, plant, and equipment | -1.05B |
| Item | Value |
|---|---|
| Proceeds from short-term debt | 12.44B |
| Proceeds from the exercise of stock options and excess tax benefits | 1.17B |
| Credit support agreements activity, net | -109.00M |
| Other | -588.00M |
| Repayments of senior debt | -2.00B |
| Payments of ordinary dividends | -3.13B |
| Repayments of short-term debt | -3.22B |
| Payments for repurchase of common stock | -4.03B |
| Item | Value |
|---|---|
| Cash and cash equivalents, beginning of period | 19.71B |
| Cash and cash equivalents, end of period | 21.69B |
Instantly decode complex 10-K and 10-Q data. Explore interactive Sankey diagrams for income and balance sheets, and intuitive waterfall charts for cash flows.
Search for a company and select a report on the left panel.
Request Stock Support